Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Uterine Cervical Neoplasms 2Solid Tumor 2Nasopharyngeal Carcinoma 2Gastrointestinal Stromal Tumors 2Colorectal Neoplasms 2Carcinoma, Renal Cell 2Carcinoma, Non-Small-Cell Lung 2Recurrence 1Non-squamous Non-small-cell Lung Cancer 1Non Squamous Non Small Cell Lung 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Advanced Solid Tumor 1Advanced NSCLC 1

Interventions

lutetium Lu 177 dotatate 3Octreotide 3pasireotide 2lanreotide 2amino-acid, glucose, and electrolyte solution 2Everolimus 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2famitinib 1copper dotatate CU-64 1arginyllysine 1Temozolomide 1Sunitinib 1Receptor-Like Protein Tyrosine Phosphatases, Class 2 1PM 01183 1Oxaliplatin 1Lutetium-177 1Lutetium 1Leucovorin 1Irinotecan 1Folfox protocol 1Fluorouracil 1E-7386 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Gastro-enteropancreatic neuroendocrine tumor × famitinib × Clear all
NCT01994213 2019-01-22

A Study of Famitinib in Patients With Advanced or Metastatic Gastroenteropancreatic Neuroendocrine Tumor

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Terminated
53 enrolled
EndocrineGastrointestinalNET

Gastro-enteropancreatic neuroendocrine tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡